Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Investor Presentation (April 2026)
23 slides from Glucotrack's investor presentation, April 2026
Slide 1: Advancing Diabetes Management
Advancing Diabetes Management Introducing Continuous Blood Glucose Monitoring April 2026 © Copyright 2026. All rights reserved. Glucotrack.
Slide 2: Important Disclaimers
IMPORTANT DISCLAIMERS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limitin
Slide 3: Redefining Glucose Monitoring
REDEFINING GLUCOSE MONITORING Implantable CBGM Continuous Blood Glucose Monitoring No Wearables Long-term Monitoring Direct Blood Sensing 3 © Copyright 2026. All rights reserved. Glucotrack.
Slide 4: CBGM: Advanced Monitoring, Expanding Market
CBGM: ADVANCED MONITORING, EXPANDING MARKET SOLUTION MARKET VALIDATION $13.4B1 Global CGM Market First-in-human safety demonstrated Direct Blood Sensing Fully Implantable ~50% Feasibility study complete (OUS) IDE process initiated of Patients Underserved 3-Year Longevity ISO 13485 certified No Weara
Slide 5: An Experienced Team
AN EXPERIENCED TEAM Paul V. Goode, PhD Drinda Benjamin, MBA Sandie Martha, MS President & CEO VP, Clinical Operations Mark Tapsak, PhD VP, Marketing • Glucose monitoring • Glucose monitoring Chief Scientific Officer • Glucose monitoring • Implantable cardiac devices • Cardiology • Glucose monitoring
Slide 6: Diabetes Innovation Can't Wait
DIABETES INNOVATION CAN’T WAIT The growing burden is placing enormous strain on healthcare resources 2x higher risk ~40% develop >25% spending Heart disease or stroke Chronic kidney disease Linked to diabetes 1 in 10 adults 40 million Americans References: CDC/National Center for Health Statistics,
Slide 7: CGM Adoption Is Accelerating
CGM ADOPTION IS ACCELERATING Yet More Than Half the Market Remains Untapped Diabetes Technology Quarterly Revenue (M)1 $13.4B Global CGM Market (2025) $6,000 Total CGM ~50% of revenue generated in US $5,500 Insulin Pumps $4,500 Q4 2025 revenue of $3.6B $3,500 $3,555 +12% year over year $2,500 $1,500
Slide 8: CGM Focus Is Shifting to Lower-Risk
CGM FOCUS IS SHIFTING TO LOWER-RISK Adoption is expanding beyond the highest-need populations Diabetes Segments by Size & Penetration (M)1 25.0M 30 25 5 Patients with daily monitoring needs & broad insurance coverage 20 4 15 3 2 10 1 5 2M 2.5M 3.5M 3.5M 25M 0 0 Type 1 Type 2 Insulin Intensive Type 2
Slide 9: The Technology Still Has Limits
CGM was a breakthrough, but… THE TECHNOLOGY STILL HAS LIMITS While CGM improved outcomes, adoption and long-term adherence fall below expectations CGM Benefits CGM Limitations Continuous Monitoring Wearable Burden 24/7 wearable sensor Adhesive irritates skin Glucose trends Sensors fall off interferi
Slide 10: What Patients Want, But Are Still Not Getting
WHAT PATIENTS WANT, BUT ARE STILL NOT GETTING Unaddressed patient needs growing in importance 70% 2018 2025 60% 50% 40% 30% 20% 10% 44% 57% 39% 40% 32% 40% 27% 28% 22% 31% 21% 37% 0% Longer sensor wear Shorter sensor Better accuracy Smaller, thinner Better sensor Longer transmission warmup time CGM
Slide 11: A Breakthrough CBGM System
The Glucotrack Solution: A BREAKTHROUGH CBGM SYSTEM A first-of-its-kind system that combines Designed from FDA-approved components the best of glucose monitoring and cardiac and adopted techniques to accelerate monitoring technology in one device development and reduce regulatory risk Axillary Vein
Slide 12: Cardiology Implant Specialists Already See Patients with Diabetes
CARDIOLOGY IMPLANT SPECIALISTS ALREADY SEE PATIENTS WITH DIABETES Patients with Diabetes Seen by Specialist in Past 12 Months 50% DIABETES IS A CARDIOLOGY CARDIOMETABOLIC 40% IMPLANT DISEASE 30% SPECIALISTS Strongly associated with Atherosclerotic Experienced in active implantable Cardiovascular Dis
Slide 13: Putting Risk in Perspective
PUTTING RISK IN PERSPECTIVE The real threat is uncontrolled diabetes Implant complications are very low1 Severe Hypoglycemic Event (SHE) risk (≥1 in previous 12 months)2, even with wearable Glucotrack’s CBGM is even less complex CGM, far exceeds implantation risk • Simpler procedure • Seizures • Sma
Slide 14: What Makes Our CBGM Different?
WHAT MAKES OUR CBGM DIFFERENT? Implant once. Monitor for years. Designed to deliver up to 3 years of continuous monitoring with blood-true accuracy without no external wearables or daily upkeep. LONGEVITY DESIGN ACCURACY One sensor. No skin adhesive. Blood-true sensing. Three years. No bulky wearabl
Slide 15: CGM Focus Is Shifting to Lower-Risk
CGM FOCUS IS SHIFTING TO LOWER-RISK Adoption is expanding beyond the highest-need populations Diabetes Segments by Size & Penetration (M)1 25.0M 30 25 5 Patients with daily monitoring needs & broad insurance coverage 20 4 15 3 2 10 1 5 2M 2.5M 3.5M 3.5M 25M 0 0 Type 1 Type 2 Insulin Intensive Type 2
Slide 16: CBGM Targeted Populations
CBGM TARGETED POPULATIONS Four targeted segments rely on CGM daily Diabetes Segments by Size (M) 25.0M ~11.4M people 30 25 5 Patients with daily monitoring needs & 4 with clinical consensus and broad coverage broad insurance coverage 20 15 3 2 10 1 2017: CMS coverage of CGM for T1D 5 2M 2.5M 3.5M 3.
Slide 17: Large Market Opportunity for CBGM
LARGE MARKET OPPORTUNITY FOR CBGM According to research, ~1 in 4 TAM patients are willing to receive an implant ~3.2M target patients 11.4M patients rely on CGM daily WHY CBGM MATTERS Reduces CGM “tech burnout” Increases long-term adherence Improves confidence Patients frequently report fatigue from
Slide 18: First-in-Human Study Demonstrates Feasibility
FIRST-IN-HUMAN STUDY DEMONSTRATES FEASIBILITY Prototype implant demonstrated reliable continuous glucose monitoring 36-hour glucose monitoring including FST 1; MARD=5.9% Study Overview • 8 participants with T1D or T2D 400 using intensive insulin 350 CBGM Glucose • Sensor lead implanted with 300 Bloo
Slide 19: Early Data Show Strong Sensor Accuracy
EARLY DATA SHOW STRONG SENSOR ACCURACY Performance vs reference blood glucose measurements Continuous Measurements vs Reference 91.6% DTS Error Grid CBGM incl. Calibration Points 450 400 400 Measurement Glucose (mg/dL) MARD within green Measurement Glucose (mg/dL) 350 350 300 Clarke/Parkes 7.7% 300
Slide 20: Clinical and Regulatory Timeline
CLINICAL AND REGULATORY TIMELINE Leveraging proven regulatory strategies – DeNovo 510k Pathway FDA DeNovo 510k submission (1-year data) US Pilot IDE US Pivotal US Pivotal approval submission begins 2026 2027 2028 2029 US Pivotal US Pilot IDE US Pilot IDE enrollment US Pivotal 1 year FDA Approval beg
Slide 21: Engineered for What Patients Want
ENGINEERED FOR WHAT PATIENTS WANT (and Wearable CGMs Can’t Deliver) Unsurpassed longevity Placed once every 3 years 20-minute outpatient procedure Wearable-free comfort Fully implantable design No on-body devices Real-time blood glucose readings Uses blood-true sensing Greater accuracy and trust Sim
Slide 22: Poised for Impact. Positioned for Growth.
POISED FOR IMPACT. POSITIONED FOR GROWTH. Glucotrack is pioneering a fully implantable, long-term CBGM designed to overcome the limitations of wearable CGMs ADOPTION MOMENTUM CONVERSION SCALE Unlock adoption among Capitalize on strong Convert CGM users Expand through regulatory the >50% of patients
Slide 23: Thank You
Thank You 23 © Copyright 2026. All rights reserved. Glucotrack.